Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference
Universal Ibogaine Inc. announced that its co-founder, Dr. Alberto Sola, will present at the Global Summit on Psychedelic Assisted Therapies in Toronto from May 27 to 29, 2022. Dr. Sola, an expert in ibogaine detox treatments, will discuss his findings on Ibogaine Hydrochloride and Acute Opioid Detox on May 28 at 4:15 PM EST. The summit is organized by the Mental Health Commission of Canada and will feature policy makers and researchers, including attendees from Health Canada and the FDA. The event is seen as a vital step toward advancing addiction treatment and awareness.
- None.
- None.
CALGARY, AB, May 13, 2022 /PRNewswire/ - Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will present at the May 27 to 29 event: From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine which will be held in Toronto, Canada from May 27 to 29, 2022.
The Research to Reality event is presented by the Mental Health Commission of Canada, the Center for Addiction and Mental Health ("CAMH") and the Canadian Center on Substance Abuse and Addiction.
The event will be attended by researchers, clinicians' policy makers including representatives from Health Canada the FDA and the Mexico Ministry of Health ("COFEPRIS").
Dr. Sola, is a co-founder of Universal Ibogaine and a member of the Board of Directors, and he is the founder of the Clear Sky Recovery ibogaine clinic operating in Cancun, Mexico. Alberto is a global leader in ibogaine detox treatments. He will present his latest findings in a panel titled "Ibogaine Hydrochloride and Acute Opioid Detox., which will take place on Saturday May 28 at 4:15 PM EST"
UI CEO Nick Karos noted: "The importance of this event cannot be overstated. This is the first event of its kind to bring together academic researchers, real world technicians and government policy makers. We believe this event will be an important catalyst for the industry and a significant milestone for our company. This event will create awareness at the highest levels of the incredible potential of ibogaine."
UI is a life sciences company, with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", "potential", or other similar words, or statements that certain events or conditions "may", "should" or "could" occur. The forward-looking statements and information are based on certain key expectations and assumptions made by UI. Although UI believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because UI can give no assurance that they will prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions as of the date hereof. UI does not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
Related Links
https://universalibogaine.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/universal-ibogaine-co-founder-dr-alberto-sola-to-present-at-upcoming-research-to-reality-conference-301547153.html
SOURCE Universal Ibogaine Inc.
FAQ
What is Universal Ibogaine Inc. presenting at the May 2022 summit?
Who is Dr. Alberto Sola?
When and where is the Global Summit on Psychedelic Assisted Therapies happening?
What are the goals of the summit attended by Universal Ibogaine Inc.?
What importance does Universal Ibogaine Inc.'s CEO attribute to the summit?
